CenterBook Partners LP Acquires 21,051 Shares of IQVIA Holdings Inc. $IQV

CenterBook Partners LP boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 315.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,730 shares of the medical research company’s stock after buying an additional 21,051 shares during the period. CenterBook Partners LP’s holdings in IQVIA were worth $5,267,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Physician Wealth Advisors Inc. raised its stake in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. boosted its position in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the period. Atlantic Union Bankshares Corp purchased a new position in IQVIA during the third quarter valued at approximately $36,000. Root Financial Partners LLC bought a new stake in IQVIA during the 3rd quarter worth approximately $43,000. Finally, Hantz Financial Services Inc. lifted its stake in IQVIA by 92.0% in the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after purchasing an additional 115 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

IQV has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Citigroup decreased their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. JPMorgan Chase & Co. lowered their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Finally, Truist Financial raised their target price on shares of IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $238.20.

IQVIA Stock Down 1.5%

Shares of IQV opened at $164.44 on Wednesday. The firm has a market cap of $28.00 billion, a P/E ratio of 20.92, a P/E/G ratio of 1.61 and a beta of 1.37. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock has a 50 day simple moving average of $220.91 and a two-hundred day simple moving average of $208.93. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same period in the previous year, the business posted $3.12 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.